echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Which pharmaceutical companies are on the 2019 national technological innovation demonstration enterprise list?

    Which pharmaceutical companies are on the 2019 national technological innovation demonstration enterprise list?

    • Last Update: 2019-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [pharmaceutical network industry trends] recently, the Ministry of industry and information technology released the review and evaluation results of national technological innovation demonstration enterprises in 2019 It is understood that 148 national technological innovation demonstration enterprises identified and reviewed in 2016 have been reviewed and evaluated A total of 145 enterprises have passed the review and evaluation, of which 19 pharmaceutical enterprises have been selected, including Tianshili Pharmaceutical Group Co., Ltd., Yangzijiang Pharmaceutical Group, Furen Pharmaceutical Group Co., Ltd., Shenwei Pharmaceutical Technology Co., Ltd., Shandong Luoxin Pharmaceutical Co., Ltd Group Co., Ltd., Kangmei Pharmaceutical Co., Ltd., Zhejiang Jiuzhou Pharmaceutical Co., Ltd., Kunming Pharmaceutical Group Co., Ltd., Shanxi Zhendong Pharmaceutical Co., Ltd., Ruiyang Pharmaceutical Co., Ltd., Wuhan Qirui Pharmaceutical Co., Ltd., Kangyue Pharmaceutical Group Co., Ltd., Qilu Pharmaceutical Co., Ltd., Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd( Hainan) Co., Ltd., Tianjin HongRi Pharmaceutical Co., Ltd., Shenzhen Mindray biomedical electronic Co., Ltd., Shanghai minimally invasive medical devices (Group) Co., Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd Next, the author briefly introduces the innovation and development of five pharmaceutical enterprises In order to meet the nearly strict requirements of safety and quality standards for international drug research and drug regulation, tisley has created the fifth generation of dropping pill machine with high frequency and deep cold dropping technology In view of the three "mismatches" in the process of internationalization of traditional Chinese medicine, Tianshili has done the following: first, establish the quality control system in the process of selection, planting, collection and treatment of traditional Chinese medicine from the source, realize the standardized management and quality assurance of the whole process of traditional Chinese medicine resources, and break through the "bottleneck" that plagues the modern traditional Chinese medicine industry 2 Create a new mode of modern research and industrialization of new Chinese medicine led by "component Chinese medicine" By clarifying the material basis and mechanism of action, traditional Chinese medicine, which used to be vague and unclear, has achieved a clear material basis of action and mechanism of action, opening the mysterious "black box" of Chinese medicine 3 Carry out scientific design and in-depth research on the production process, determine the relationship between quality attributes and production parameters, and ensure the quality stability of the production process 4 The whole production process shall be standardized, automated and data-based to ensure stable quality and consistency between batches It is understood that Yangzijiang established the Research Institute of traditional Chinese medicine in 2009 to research and explore some products that can treat difficult and miscellaneous diseases More than 10 innovative Chinese medicine projects are under research, covering cardio cerebrovascular, endocrine, gynecology, pediatrics and digestive system In the process of development, Yangtze River said that source control is a step of modernization According to the gap standard requirements of Chinese herbal medicine issued by the state, it has established more than ten standardized production bases of Chinese herbal medicine, such as Banlangen, gardenia, astragalus, etc., in the genuine herbal medicine production areas of Shaanxi, Gansu, Sichuan, Chongqing and Hunan, with a planting area of about 70000 mu The standardized management is implemented from the seed resources of medicinal materials, including various raw medicinal materials in the formula of Lanqin oral liquid, Weisu granules, ginkgo leaves, etc., which realizes the whole process control from the source of medicinal materials to the products In order to find a stable drug source, the Yangtze River has spread all over the country in recent years From the gene and composition of seeds to the soil, weather and environment of the producing area, a variety of medicinal materials have been systematically analyzed and investigated on the spot Furen pharmaceutical "the way out for enterprises is innovation, but innovation is not a problem of money Enterprises need to integrate multiple elements, including culture and thinking, to determine the degree of innovation of enterprises." It is understood that Furen pharmaceutical has invested heavily in strengthening the construction of innovation platform, strategically arranging three R & D innovation platforms, including Zhengzhou Technology R & D and international cooperation platform, Beijing innovation R & D platform, and Shanghai Traditional Chinese medicine R & D platform, with nearly 600 R & D innovation teams, opening up a new development path of R & D driven innovation According to reports, as early as 2012, Furen pharmaceutical industry has carried out large-scale innovation By 2021, new drugs will occupy the leading position The company will transfer all its research and development energy to new drug research and development, and the company will have 10 innovative drugs into clinical practice " According to the annual report, in 2018, R & D expenses of Furen pharmaceutical industry reached 2289393000 yuan, an increase of 22.7853 million yuan or 11.05% over the previous year Shenwei pharmaceutical "technological innovation is the lifeline of the enterprise, we will continue to increase the intensity of innovation, using technology to change human life." It is reported that Shenwei is studying and developing DNA identification technology for Chinese herbal medicines At that time, each Chinese herbal medicine will have a unique "gene ID card", which can be quickly distinguished from the counterfeit   It is understood that in the process of continuous innovation, Shenwei pharmaceutical has gradually built and improved a three-level R & D system: for the Research Institute, focusing on the construction of product process technology and new technology platform and new product R & D; the second level is the technology department and the medical department, focusing on the market, mainly solving drug safety problems, and the technology department is mainly responsible for product technology upgrading; the third level is Person in charge of production workshop and technologist, test production technical data, etc Luoxin pharmaceutical takes R & D and innovation as the core driving force for the long-term development of the enterprise In recent years, the R & D expenses account for more than 6% of the revenue The R & D path of "from imitation to creation, combination of imitation and creation" is adopted, focusing on the R & D in the fields of anti-tumor, cardiovascular system, chemical elimination system, respiratory system, anti infection and other small molecule therapy Luoxin pharmaceutical has established a three in one scientific research and production system including Shanghai Scientific Research Center, Linyi Research Institute and Hengxin pharmaceutical R & D center Shanghai Scientific Research Center is mainly engaged in the development of innovative drugs, research on the consistency evaluation of generic drugs, industry university research cooperation and international technology introduction; Linyi Research Institute is mainly engaged in the development of generic drugs and the consistency evaluation of generic drugs; Hengxin pharmaceutical research and development center is fully responsible for the innovation and development of APIs.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.